Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   Plasma and CNS pharmacokinetics of O(4)-benzylfolic acid (O(4)BF) and metabolite in a non-human primate model
  2. Chuk, M. K.; Cole, D. E.; McCully, C.; Loktionova, N. A.; Pegg, A. E.; Parker, R. J.; Pauly, G.; Widemann, B. C.; Balis, F. M.; Fox, E.
  3. Cancer Chemotherapy and Pharmacology. 2011, Jun; 67(6): 1291-1297.
  1. 2.   In vitro comparison of O4-benzylfolate modulated, BCNU-induced toxicity in human bone marrow using CFU-GM and tumor cell lines
  2. Behrsing, H. P.; Furniss, M. J.; Robillard, K. A.; Tomaszewski, J. E.; Parchment, R. E.
  3. Cancer Chemotherapy and Pharmacology. 2010, May; 65(6): 1083-1091.
  1. 3.   Inactivation of O-6-Alkylguanine-DNA alkyltransferase by folate esters of O-6-Benzyl-2'-deoxyguanosine and of O-6- 4-(Hydroxymethyl)benzyl guanine
  2. Javanmard, S.; Loktionova, N. A.; Fang, Q.; Pauly, G. T.; Pegg, A. E.; Moschel, R. C.
  3. Journal of Medicinal Chemistry. 2007, Oct; 50(21): 5193-5201.
  1. 4.   Role of GADD34 in modulation of cisplatin cytotoxicity
  2. Fishel, M. L.; Rabik, C. A.; Bleibel, W. K.; Li, X. M.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2006, JAN 12; 71(3): 239-247.
  1. 5.   Phase I trial of temozolomide plus O-6-benzylguanine for patients with recurrent or progressive malignant glioma
  2. Quinn, J. A.; Desjardins, A.; Weingart, J.; Brem, H.; Dolan, M. E.; Delaney, S. M.; Vredenburgh, J.; Rich, J.; Friedman, A. H.; Reardon, D. A.; Sampson, J. H.; Pegg, A. E.; Moschel, R. C.; Birch, R.; McLendon, R. E.; Provenzale, J. M.; Gururangan, S.; Dancey, J. E.; Maxwell, J.; Tourt-Uhlig, S.; Herndon, J. E.; Bigner, D. D.; Friedman, H. S.
  3. Journal of Clinical Oncology. 2005, OCT 1; 23(28): 7178-7187.
  1. 6.   Role of glutathione and nucleotide excision repair in modulation of cisplatin activity with O-6-benzylguanine
  2. Fishel, M. L.; Ganicsik, M. P.; Delaney, S. M.; Zuhowski, E. G.; Maher, V. M.; Karrison, T.; Moschel, R. C.; Egorin, M. J.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2005, APR; 55(4): 333-342.
  1. 7.   Effect of cell cycle inhibition on cisplatin-induced cytotoxicity
  2. Fishel, M. L.; Newell, D. R.; Griffin, R. J.; Davison, R.; Wang, L. Z.; Curtin, N. J.; Zuhowski, E. G.; Kasza, K.; Egorin, M. J.; Moschel, R. C.; Dolan, M. E.
  3. Journal of Pharmacology and Experimental Therapeutics. 2005, JAN; 312(1): 206-213.
  1. 8.   Brain tumor cell lines resistant to O-6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O-6 -alkylguanine-DNA alkyltransferase mutations
  2. Bacolod, M. D.; Johnson, S. P.; Pegg, A. E.; Dolan, M. E.; Moschel, R. C.; Bullock, N. S.; Fang, Q. M.; Colvin, O. M.; Modrich, P.; Bigner, D. D.; Friedman, H. S.
  3. Molecular Cancer Therapeutics. 2004, SEP; 3(9): 1127-1135.
  1. 9.   The repair of the tobacco specific nitrosamine derived adduct O-6-[4-oxo-4-(3-pyridyl)butyl]guanine by O-6-alkylguanine-DNA alkyltransferase variants
  2. Mijal, R. S.; Thomson, N. M.; Fleischer, N. L.; Pauly, G. T.; Moschel, R. C.; Kanugula, S.; Fang, Q. M.; Pegg, A. E.; Peterson, L. A.
  3. Chemical Research in Toxicology. 2004 17(3): 424-434.
  1. 10.   Repair of oligodeoxyribonucleotides by O-6-alkylguanine-DNA alkyltransferase
  2. Luu, K. X.; Kanugula, S.; Pegg, A. E.; Pauly, G. T.; Moschel, R. C.
  3. Biochemistry. 2002 41(27): 8689-8697.
  1. 11.   Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism
  2. Long, L.; Moschel, R. C.; Dolan, M. E.
  3. Biochemical Pharmacology. 2001 61(6): 721-726.
  1. 12.   Inactivation of O-6-alkylguanine-DNA alkyltransferase by 8- substituted O-6-benzylguanine analogs in mice
  2. Ewesuedo, R. B.; Wilson, L. R.; Friedman, H. S.; Moschel, R. C.; Dolan, M. E.
  3. Cancer Chemotherapy and Pharmacology. 2001 47(1): 63-69.
  1. 13.   Thresholds of O-6-alkylguanine-DNA alkyltransferase which confer significant resistance of human glial tumor xenografts to treatment with 1,3-bis(2-chloroethyl)-1-nitrosourea or temozolomide
  2. Kokkinakis, D. M.; Bocangel, D. B.; Schold, S. C.; Moschel, R. C.; Pegg, A. E.
  3. Clinical Cancer Research. 2001 7(2): 421-428.
  1. 14.   Inactivation of human O-6-alkylguanine-DNA alkyltransferase by modified oligodeoxyribonucleotides containing O-6-benzylguanine
  2. Pegg, A. E.; Goodtzova, K.; Loktionova, N. A.; Kanugula, S.; Pauly, G. T.; Moschel, R. C.
  3. Journal of Pharmacology and Experimental Therapeutics. 2001 296(3): 958-965.
  1. 15.   Reaction of O-6-Benzylguanine-Resistant Mutants of Human O-6-Alkylguanine-Dna Alkyltransferase With O-6-Benzylguanine in Oligodeoxyribonucleotides
  2. Pegg, A. E.; Kanugula, S.; Edara, S.; Pauly, G. T.; Moschel, R. C.; Goodtzova, K.
  3. Journal of Biological Chemistry. 1998 273(18): 10863-10867.
  1. 16.   O-6-Alkylguanine-Dna Alkyltransferase Inactivation By Ester Prodrugs of O-6-Benzylguanine Derivatives and Their Rate of Hydrolysis By Cellular Esterases
  2. Dolan, M. E.; Roy, S. K.; Garbiras, B. J.; Helft, P.; Paras, P.; Chae, M. Y.; Moschel, R. C.; Pegg, A. E.
  3. Biochemical Pharmacology. 1998 55(10): 1701-1709.
  1. 17.   Intraarterial O-6-Benzylguanine Enables the Specific Therapy of Nitrosourea-Resistant Intracranial Human Glioma Xenografts in Athymic Rats With 1,3-Bis(2-Chloroethyl)-1-Nitrosourea
  2. Kurpad, S. N.; Dolan, M. E.; McLendon, R. E.; Archer, G. E.; Moschel, R. C.; Pegg, A. E.; Bigner, D. D.; Friedman, H. S.
  3. Cancer Chemotherapy and Pharmacology. 1997 39(4): 307-316.
  1. 18.   Effect of Dna On the Inactivation of O-6-Alkylguanine-Dna Alkyltransferase By 9-Substituted O-6-Benzylguanine Derivatives
  2. Pegg, A. E.; Chung, L.; Moschel, R. C.
  3. Biochemical Pharmacology. 1997 53(10): 1559-1564.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel